Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1995-05-18
1997-07-29
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530350, 530395, 514 8, 435 691, C12N 1512, C07K 14715, A61K 3817
Patent
active
056522100
ABSTRACT:
The invention provides soluble forms of the Fas (Apo-1) protein comprising both the intracellular and extracellular domains of the full-length polypeptide. Exemplified is a naturally-occurring splice variant of the Fas gene, Fas.DELTA.TM, which lacks the transmembrane domain of the native antigen. DNA encoding the protein, cells expressing the recombinant DNA, and methods of using the protein and DNA are also provided.
REFERENCES:
Wyllie, "Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation" Nature (1980) 284:555-556.
Kruman et al., "Apoptosis of murine BW 5147 thymoma cells induced by dexamethasone and .gamma.-irradiation" J. Cell. Physiol. (1991) 148:267-273.
Itoh et al., "The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis" Cell (1991) 66:233-243.
Krammer et al., "Apoptosis in the APO-1 system" Apoptosis: The Molecular Basis of Cell Death (1991) Tomei et al., eds., Cold Spring Harbor Laboratory Press, New York, pp. 87-99.
Oehm et al., "Purification and molecular cloning of the APO-1 cell surface antigen, a member of the tumor necrosis factor
erve growth factor receptor superfamily" J. Biol. Chem. (1992) 267:10709-10715.
Rouvier et al., "Fas involvement in Ca.sup.2+ -independent T cell-mediated cytotoxicity" J. Exp. Med. (1993) 177:195-200.
Ogasawara et al., "Lethal effect of the anti-Fas antibody in mice" Nature (1993) 364:806-809.
Zhu et al., "Systemic gene expression after intravenous DNA delivery into adult mice" Science (1993) 261:209-211.
Zapf et al., "Isolation from adult human serum of four insulin-like growth factor (IGF) binding proteins and molecular cloning of one of them that is increased by IGF I administration and in extrapancreatic tumor hypoglycemia" J. Biol. Chem. (1990) 265:14892-14898.
Wu et al., "Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene" J. of Exper. Med. (1993) 178:461-468.
Kanter et al., "Epidermal growth factor and tumor promoters prevent DNA fragmentation by different mechanisms" Biochem. Biophys. Res. Comm. (1984) 118:392-399.
Hsu et al., "Differential expression and ligand binding properties of tumor necrosis factor receptor chimeric mutants" J. Biol. Chem. (1993) 268:16430-16436.
Suda et al., "Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family" Cell (1993) 75:1169-1178.
Loenen et al., "The CD27 membrane receptor, a lymphocyte-specific member of the nerve growth factor receptor family, gives rise to a soluble form by protein processing that does not involve receptor endocytosis" Eur. J. Immunol. (1992) 22:447-455.
Cheng, J., et al. (1993) Arthritis and Rheumatism 36 (9 Suppl.): S76 (Abst. No. 228).
Cheng, J., et al. (1994) Science 263: 1759-62.
Cascino, I., et al. (1995) J. Immunol. 154: 2706-13.
Barr Philip J.
Kiefer Michael C.
Shapiro John P.
Fitzgerald David L.
LXR Biotechnology Inc.
LandOfFree
Soluble splice variant of the Fas (APO-1) antigen, Fas.DELTA.TM does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble splice variant of the Fas (APO-1) antigen, Fas.DELTA.TM, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble splice variant of the Fas (APO-1) antigen, Fas.DELTA.TM will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-633698